Core Insights - Turn Therapeutics has appointed Arthur Golden to its Board of Directors to enhance governance, oversight, and strategic execution as the company advances its late-stage programs [1][3] - Mr. Golden brings over 40 years of experience in corporate law, governance, and strategic advisory, particularly in M&A transactions and regulatory affairs [2][4] - The appointment is expected to strengthen Turn's position for long-term growth and value creation, especially as it navigates critical phases in its development [3] Company Overview - Turn Therapeutics is a clinical-stage biotechnology company focused on developing next-generation therapies for dermatology, wound care, and infectious diseases [1][6] - The company has received three FDA clearances for its proprietary formulations and is advancing late-stage clinical programs in eczema and onychomycosis [6] - Turn is also engaged in global health initiatives, including thermostable vaccine delivery aimed at underserved areas [6] Leadership Experience - Arthur Golden has extensive experience advising multinational organizations on regulatory, operational, and corporate development functions [2][4] - He has served as a Director for several NYSE companies for over 30 years and has been recognized for excellence in corporate and governance advisory [5] - His role as Senior Counsel at Davis Polk & Wardwell LLP has equipped him with insights into guiding Fortune 500 companies through transformative transactions [2][4]

Core Insights - The U.S. IPO market remains active despite government shutdown, with 6 traditional IPOs and 2 SPACs launched this week, alongside 13 companies filing for initial public offerings [1][12]. Group 1: IPO Activity - Alliance Laundry Holdings (ALH) raised $826 million, pricing at the upper limit of its range, achieving a market cap of $4.5 billion, and saw a 14% stock price increase [1]. - Phoenix Education Partners (PXED) raised $136 million, pricing at the midpoint of its range, with a market cap of $1.3 billion and a 13% stock price increase [1]. - Ping An Good Doctor (POM) raised $20 million, pricing at the lower limit of its range, with a market cap of $474 million and a 9% stock price increase [2]. - One and One Green Tech (YDDL) raised $10 million, pricing at the midpoint of its range, achieving a market cap of $27 million and a significant 31% stock price increase [2]. - Leifras (LFS) raised $5 million, pricing at the lower limit of its range, with a market cap of $10.5 million, but experienced a 5% stock price decline [2]. - Turn Therapeutics (TTRX) debuted via direct listing at $10, but saw a 26% decline in stock price [3]. Group 2: SPAC Activity - Two SPACs completed their listings: GigCapital8 (GIWWU) raised $220 million and Lake Superior Acquisition (LKSPU) raised $100 million, focusing on energy, social media, and consumer goods [4]. - Five SPACs filed for IPOs, including Xsolla SPAC 1 (XSOLU.RC) and Alussa Energy Acquisition II (ALUBU), both aiming to raise $250 million [8][10]. Group 3: Upcoming IPOs and Market Trends - 13 companies filed for IPOs, including BillionToOne (BLLN), Evommune (EVMN), and Central Bancompany (CBC), each planning to raise $100 million [6]. - The SEC issued new guidelines allowing companies to announce pricing ranges and set final pricing above the range, which may encourage more companies to proceed with listings amid the government shutdown [12].

Core Viewpoint - Turn Therapeutics (TTRX.US) stock price surged over 144%, reaching $16.95, indicating strong market interest and potential investor confidence in the company's innovative therapies [1] Company Overview - Turn Therapeutics focuses on developing next-generation therapies for skin diseases, wounds, and infections [1] - The company utilizes a proprietary delivery platform technology called "PermaFusion®" [1] Technology and Innovation - The "PermaFusion®" technology allows water-soluble active ingredients to penetrate the skin, nails, or mucous membranes using an oil-based carrier without the need for emulsifiers [1] - This technology aims to enhance the availability of active ingredients while reducing irritation [1]

Company Overview - Turn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing next-generation dermatology, wound care, and anti-infective therapies [5] - The company is based in California and recently commenced trading on the Nasdaq Capital Market [2] Market Performance - Turn Therapeutics' shares surged by 134.29% after the market closed on Wednesday, reaching a closing price of $16.40 [1] - During regular trading on the same day, TTRX shares fell by 26.47%, closing at $7.00 [5] Nasdaq Listing - The Securities and Exchange Commission (SEC) declared Turn's registration statement on Form S-1 effective on September 30 [2] - The Nasdaq Exchange welcomed Turn Therapeutics on social media, highlighting its innovative approach in pharmaceutical technologies [2] Leadership Insights - Bradley Burnham, the founder and CEO, emphasized the company's lean operating model, stating it was "built on a shoestring, with an absolute disdain for waste" [3] Closing Bell Ceremony - Turn Therapeutics participated in the closing bell ceremony at Nasdaq's MarketSite in New York, which was broadcast live [4]

Core Insights - U.S.-listed biotech and healthcare stocks experienced significant bullish activity in after-hours trading, with Turn Therapeutics Inc. leading the surge with a 134.29% increase to $16.40 following its Nasdaq debut [1] Group 1: Company Performances - Talphera Inc. reached a new 52-week high in regular trading and added 4.55% after hours to close at $1.38, driven by momentum despite no new updates [2] - Personalis Inc. rose 1.50% to $8.81 in after-hours trading, having hit a 52-week high earlier in the day, likely due to ongoing investor interest in precision oncology [2] - Ionis Pharmaceuticals Inc. climbed 3.64% to $72.51 after hours, supported by its Innovation Day presentation and reaffirmation of its pipeline strategy, leading to a new 52-week high during regular trading [3] - Sensei Biotherapeutics Inc. increased 5.23% to $12.08, with anticipation building ahead of its pipeline updates scheduled for October 20 [3] - Corbus Pharmaceuticals Holdings Inc. gained 4.77% to $14.06, preparing for participation in the Piper Sandler Virtual Oncology Symposium on October 9 [4] - Longeveron Inc. advanced 5.71% to $0.9801, with expectations for insights into its regenerative medicine pipeline at the ROTH Healthcare Opportunities Conference [4] - Palisade Bio Inc. rose 5.00% to $2.10 in after-hours trading, buoyed by a recent $138 million public offering that strengthened its balance sheet ahead of Phase 2 trials [5] Group 2: Market Trends - The after-hours session showcased a mix of technical breakouts, event-driven anticipation, and momentum trading, indicating a fertile environment for volatility and investment opportunities in the biotech sector [6]

Founder & CEO, Bradley Burnam, to Ring NASDAQ “Closing Bell” at 4:00 PM ETWESTLAKE VILLAGE, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (“Turn” or the “Company”), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, announces that its common stock is scheduled to commence trading today, October 8, 2025, on the Nasdaq Capital Market under ticker symbol “TTRX.” The Company’s registration statement on Form S-1 was declared effectiv ...

Core Insights - Turn Therapeutics, a clinical-stage biotechnology company, is set to begin trading its common stock on the Nasdaq Global Market under the ticker symbol "TTRX" on October 8, 2025 [1] Company Overview - Turn Therapeutics focuses on developing therapies in dermatology, wound care, and anti-infective sectors [1]